| Predicate | Object |
|---|---|
| rdf:type | |
| biopax3:comment |
Covalent (irreversible) TKIs, pelitinib, WZ4002, HKI-272, canertinib and afatinib, inhibit the wild-type EGFR through formation of the covalent bond with the cysteine residue C397.
|
| biopax3:xref | |
| biopax3:evidenceCode |